logo
Warwick Davis' wife's cause of death revealed as arrhythmic cardiac arrest

Warwick Davis' wife's cause of death revealed as arrhythmic cardiac arrest

Yahoo14-04-2025
Warwick Davis' wife's cause of death has been revealed as arrhythmic cardiac arrest. Samantha Davis died aged 53 on 24 March, 2024, and an inquest on Monday (14.04.25) at Inner West London Coroner's Court heard the actress – who had the achondroplasia form of dwarfism – underwent a thoracic discectomy at the National Hospital for Neurology and Neurosurgery in London on 20 February 2024 and passed away following complications linked to her spinal surgery. The procedure, intended to address semi-paralysis in her legs, involved cutting through her ribs and deflating a lung. Post-surgery, she suffered a haemothorax, leading to the drainage of approximately one litre of fluid. She was then transferred to University College London Hospital for observation.​ After a second haemothorax in March, Samantha showed signs of improvement and was scheduled for discharge on 24 March. However, she went into cardiac arrest shortly before midnight on 23 March and was pronounced dead in the early hours of the following day. Resuscitation efforts lasted 53 minutes.​ Pathologist Dr John Firth attributed her death to a left haemothorax resulting from surgical complications, noting the presence of over 700ml of blood and clots. However, some medical professionals offered differing opinions. Cardiothoracic surgeon Mr David Lawrence stated a chest x-ray taken the day before her death appeared satisfactory and suggested that the bleeding was more likely caused by CPR. Consultant spinal surgeon Mr Adrian Casey, who performed the discectomy, remarked such blood loss was 'unlikely to cause death' and described the cause as 'somewhat unexplained'. Dr Katherine Hunt, UCLH's clinical lead for resuscitation, said Samantha's bleed was more likely a result of CPR and identified signs of an abnormal heart rhythm on the defibrillator rhythm strip.​ Senior Coroner Professor Fiona Wilcox concluded the actress passed away from arrhythmic cardiac arrest following complications from spinal surgical treatment. She stated: 'On the balance of probabilities, the stress of her surgeries and the complications that arose precipitated the arrhythmia.' Professor Wilcox emphasised Samantha received 'nothing but excellent care' and added: 'All of her complications were appropriately managed. It's heartbreaking that the surgery was successful only for complications to arise and cause her death."' Warwick, 55, and his family, represented by medical negligence lawyers, attended the inquest seeking clarity on the circumstances surrounding Samantha's death. In a statement released through their solicitors, the family expressed hope the inquest would provide them with answers and thanked everyone for their kindness and well-wishes.​ Samantha, who co-founded the charity Little People UK in 2012, met Warwick in 1988 on the set of the film 'Willow'. They married in 1991 and had two children, Annabelle, 27, and 21-year-old Harrison. The couple experienced the loss of two sons – Lloyd, who died at nine days old in 1991, and George, who was lost during pregnancy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citi Remains Bullish on Sana Biotechnology (SANA)
Citi Remains Bullish on Sana Biotechnology (SANA)

Yahoo

timean hour ago

  • Yahoo

Citi Remains Bullish on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Musk's Neuralink to test brain chips in clinical study in Great Britain
Musk's Neuralink to test brain chips in clinical study in Great Britain

Yahoo

time2 days ago

  • Yahoo

Musk's Neuralink to test brain chips in clinical study in Great Britain

(Reuters) - Elon Musk's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, according to media reports, citing PitchBook.

'Silent killer': the science of tracing climate deaths in heatwaves
'Silent killer': the science of tracing climate deaths in heatwaves

Yahoo

time2 days ago

  • Yahoo

'Silent killer': the science of tracing climate deaths in heatwaves

A heatwave scorching Europe had barely subsided in early July when scientists published estimates that 2,300 people may have died across a dozen major cities during the extreme, climate-fuelled episode. The figure was supposed to "grab some attention" and sound a timely warning in the hope of avoiding more needless deaths, said Friederike Otto, one of the scientists involved in the research. "We are still relatively early in the summer, so this will not have been the last heatwave. There is a lot that people and communities can do to save lives," Otto, a climate scientist at Imperial College London, told AFP. Heat can claim tens of thousands of lives during European summers but it usually takes months, even years, to count the cost of this "silent killer". Otto and colleagues published their partial estimate just a week after temperatures peaked in western Europe. While the underlying methods were not new, the scientists said it was the first study to link heatwave deaths to climate change so soon after the event in question. Early mortality estimates could be misunderstood as official statistics but "from a public health perspective the benefits of providing timely evidence outweigh these risks," Raquel Nunes from the University of Warwick told AFP. "This approach could have transformative potential for both public understanding and policy prioritisation" of heatwaves, said Nunes, an expert on global warming and health who was not involved in the study. - Big deal - Science can show, with increasing speed and confidence, that human-caused climate change is making heatwaves hotter and more frequent. Unlike floods and fires, heat kills quietly, with prolonged exposure causing heat stroke, organ failure, and death. The sick and elderly are particularly vulnerable, but so are younger people exercising or toiling outdoors. But every summer, heat kills and Otto -- a pioneer in the field of attribution science -- started wondering if the message was getting through. "We have done attribution studies of extreme weather events and attribution studies of heatwaves for a decade... but as a society we are not prepared for these heatwaves," she said. "People think it's 30 (degrees Celsius) instead of 27, what's the big deal? And we know it's a big deal." When the mercury started climbing in Europe earlier this summer, scientists tweaked their approach. Joining forces, Imperial College London and the London School of Hygiene & Tropical Medicine chose to spotlight the lethality -- not just the intensity -- of the heat between June 23 and July 2. Combining historic weather and published mortality data, they assessed that climate change made the heatwave between 1C and 4C hotter across 12 cities, depending on location, and that 2,300 people had likely perished. But in a notable first, they estimated that 65 percent of these deaths -- around 1,500 people across cities including London, Paris, and Athens -- would not have occurred in a world without global warming. "That's a much stronger message," said Otto. "It brings it much closer to home what climate change actually means and makes it much more real and human than when you say this heatwave would have been two degrees colder." - Underestimated threat - The study was just a snapshot of the wider heatwave that hit during western Europe's hottest June on record and sent temperatures soaring to 46C in Spain and Portugal. The true toll was likely much higher, the authors said, noting that heat deaths are widely undercounted. Since then Turkey, Greece and Bulgaria have suffered fresh heatwaves and deadly wildfires. Though breaking new ground, the study has not been subject to peer review, a rigorous assessment process that can take more than a year. Otto said waiting until after summer to publish -- when "no one's talking about heatwaves, no one is thinking about keeping people safe" -- would defeat the purpose. "I think it's especially important, in this context, to get the message out there very quickly." The study had limitations but relied on robust and well-established scientific methodology, several independent experts told AFP. Tailoring this approach to local conditions could help cities better prepare when heatwaves loom, Abhiyant Tiwari, a health and climate expert who worked on India's first-ever heat action plan, told AFP. "I definitely see more such studies coming out in the future," said Tiwari from NRDC India. Otto said India, which experiences tremendously hot summers, was a "prime candidate" and with a template in place it was likely more studies would soon follow. np/klm/cw/tc

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store